Advertisement
Canada markets close in 23 minutes

  • S&P/TSX

    22,014.93
    +142.97 (+0.65%)
     

  • S&P 500

    5,070.67
    +60.07 (+1.20%)
     

  • DOW

    38,503.98
    +264.00 (+0.69%)
     

  • CAD/USD

    0.7323
    +0.0022 (+0.30%)
     

  • CRUDE OIL

    83.38
    +1.48 (+1.81%)
     

  • Bitcoin CAD

    90,911.40
    +405.52 (+0.45%)
     

  • CMC Crypto 200

    1,432.32
    +17.56 (+1.24%)
     

  • GOLD FUTURES

    2,338.00
    -8.40 (-0.36%)
     

  • RUSSELL 2000

    2,004.96
    +37.49 (+1.91%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ

    15,706.62
    +255.32 (+1.65%)
     

  • VOLATILITY

    15.82
    -1.12 (-6.61%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6836
    -0.0014 (-0.20%)
     
MARKETS LIVE BLOG:

STOCKS EXTEND GAINS AS RESULTS SEASON KICKS INTO HIGH GEAR

Tech-focused investors prepare for fresh wave of earnings highlighted by struggling Tesla

Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Akero Therapeutics
Updated ·2 min read
Akero Therapeutics
Akero Therapeutics

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. P.T. in San Francisco, CA.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), is a differentiated bivalent Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). EFX is also being evaluated in an expansion cohort of the SYMMETRY study, comparing the safety and tolerability of EFX to placebo when added to an existing GLP-1 receptor agonist in patients with pre-cirrhotic NASH (F1-F3 fibrosis) and Type 2 diabetes. Akero is headquartered in South San Francisco. Visit akerotx.com and follow us on LinkedIn and Twitter for more information.

Investor Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com

Media Contact:
Sarah O’Connell
732.456.0092
soconnell@vergescientific.com